Magnesium compositions and uses thereof for neurological disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/191
A61K-031/194
A61K-033/06
A61K-035/20
A61K-033/14
A61K-009/20
A61K-009/48
A61K-045/06
A23L-033/16
출원번호
US-0805972
(2015-07-22)
등록번호
US-9616038
(2017-04-11)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Neurocentria, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
2인용 특허 :
25
초록▼
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A method of treating a neurological disorder, the method comprising orally administering to a subject in need thereof a composition comprising magnesium threonate in a dosage form, wherein: (a) the dosage form comprises at least 100 mg of magnesium threonate; (b) the magnesium threonate comprises
1. A method of treating a neurological disorder, the method comprising orally administering to a subject in need thereof a composition comprising magnesium threonate in a dosage form, wherein: (a) the dosage form comprises at least 100 mg of magnesium threonate; (b) the magnesium threonate comprises 30 mg to 1.5 g of elemental magnesium; or (c) the magnesium threonate is administered at a dose providing between 1.5 mg/kg/day to 18 mg/kg/day of elemental magnesium. 2. The method of claim 1, wherein the dosage form comprises 300 mg to 1.5 g of magnesium threonate. 3. The method of claim 1, wherein the magnesium threonate is administered at a dose providing between 1.5 mg/kg/day to 18 mg/kg/day of elemental magnesium. 4. The method of claim 1, wherein the neurological disorder is Alzheimer's disease. 5. The method of claim 1, wherein the neurological disorder is dementia. 6. The method of claim 1, wherein the neurological disorder is depression. 7. The method of claim 1, wherein the dosage form is a solid, semi-solid, semi-liquid, or a gel. 8. The method of claim 7, wherein the dosage form is a solid. 9. The method of claim 1, wherein the dosage form further comprises a nutritionally active agent. 10. The method of claim 9, wherein the nutritionally active agent is selected from the group consisting of: a calcium-containing material, an herbal, a spice, vitamin A, vitamin D, a vitamin E, a vitamin K, a vitamin B, folic acid, niacin, biotin, a mineral, and mixtures thereof. 11. The method of claim 1, wherein the dosage form is a tablet. 12. The method of claim 1, wherein the dosage form is a capsule. 13. The method of claim 1, further comprising administering the dosage form to provide an increased physiological concentration of magnesium for at least 15 days. 14. The method of claim 1, wherein the magnesium threonate is administered at a dose effective in increasing an initial physiological concentration of magnesium of the subject by at least about 10%, wherein physiological concentration is measured for the subject under a fasting condition. 15. The method of claim 14, wherein the physiological concentration is an intracellular concentration, serum concentration, plasma concentration, or cerebrospinal fluid concentration. 16. The method of claim 14, wherein the physiological concentration is measured after fasting for at least about twelve hours. 17. The method of claim 1, wherein the dosage form is a dietary supplement.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (25)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.